Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bone marrow aspirate matrix (BMA Matrix) is a biological product derived from bone marrow aspirate that forms a natural clot containing cellular and molecular components retained in a fibrin matrix. It serves as a potent orthobiologic for enhancing tissue repair mechanisms by modulating inflammation and acting as a natural biological scaffold. The matrix functions as a reservoir of cytokines and growth factors that support cell activity, displaying regenerative mechanisms similar to fracture hematomas that promote bone remodeling and healing. BMA Matrix contains mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), endothelial progenitor cells, and other progenitor cells, along with growth factors including bone morphogenetic proteins (BMP), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and IL-1 receptor antagonist.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bone marrow aspirate matrix.